Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.

Luis MezaZeynep ZenginSabrina SalgiaJasnoor MalhotraEwa KarczewskaTanya Barauskas DorffAbhishek TripathiJennifer ElyErin KelleyHeather MeadJo Ann HsuNazli DizmanNicholas SalgiaNeal ChawlaAlex Chehrazi-RaffleRamya MuddasaniAmeish GovindarajanAdam RockSandy LiuRavi SalgiaJeffrey TrentJohn AltinSumanta K Pal

Published in: The oncologist (2023)

Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination.

Keyphrases

immune response
coronavirus disease
sars cov
papillary thyroid
dendritic cells
childhood cancer
squamous cell
respiratory syndrome coronavirus
replacement therapy